Table 3.
Clinical Characteristics of the Study Population in the At-delivery Cohort.
| Group 1 | Group 2 | p Value | |
|---|---|---|---|
| Delivered for reasons other than preeclampsia (n = 21) | Delivered for preeclampsia (n = 13) | ||
| Maternal age (years) | 32 (28–42) | 31 (22–40) | NS |
| Nulliparity | 5 (24%) | 6 (46%) | NS |
| BMI before pregnancy | 20.9 (15.2–29.6) (n = 13) | 22.4 (18.4–25.6) (n = 8) | NS |
| BMI at delivery | 25.9 (20.3–33.3) (n = 17) | 27.7 (24.8–31.0) (n = 10) | NS |
| Gestational age at delivery (weeks) | 35.4 (34.3–36.9) | 35.6 (34.1–36.9) | NS |
| Birth weight (g) | 2660 (1710–3440) | 2160 (1560–3240) | < 0.01 |
| Small for gestational age | 1 (5%) | 2 (15%) | NS |
| Sex (male) | 11 (52%) | 6 (46%) | NS |
| Cesarean delivery | 17 (81%) | 13 (100%) | NS |
| Diabetes during pregnancy | 2 (10%) | 0 (0%) | NS |
| Pro- and anti-angiogenic factors | |||
| sFlt-1 (pg/mL) | 1325.0 (199.5–9884.9) | 2791.6 (723.8–7887.2) | < 0.05 |
| PlGF (pg/mL) | 31.1 (3.0–256.3) | 3.1 (1.6–40.7) | < 0.001 |
| sFlt-1/PlGF | 32.8 (7.1–3278.0) | 856.2 (59.6–3243.8) | < 0.001 |
All values are given as median (range) or number (%).
NS, not significant; BMI, body mass index; PlGF, placental growth factor; sFlt-1, soluble fms-like tyrosine kinase-1.